Kala-azar as an AIDS-related opportunistic infection

AIDS Patient Care and STDs

Volumn 13, Issue 8, 1999, Pages 459-465

  Murray, Henry W ^a,b  

^a Department of Obstetrics Gynecology   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIMONY; GAMMA INTERFERON; MEGLUMINE ANTIMONATE; MILTEFOSINE; STIBOGLUCONATE SODIUM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASPIRATION BIOPSY; CLINICAL EXAMINATION; DRUG CHOICE; HOST RESISTANCE; HUMAN; IMMUNOPATHOGENESIS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIASIS; OPPORTUNISTIC INFECTION; REVIEW; T LYMPHOCYTE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODY FORMATION; CD4 LYMPHOCYTE COUNT; EUROPE; HUMANS; LEISHMANIASIS, VISCERAL; MALE;

EID: 0032835145     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729199318183     Document Type: Review

References (31)

1. Agostoni C, Dorigoni N, Malfitano A, et al. Mediterranean leishmaniasis in HTV-infected patients: Epidemiological, clinical, and diagnostic features in 22 cases. Infection 1998;26:93-99.
2. Albrecht H, Sobottka I, Emminger C, et al. Visceral leishmaniasis emerging as an important opportunistic infection in HTV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med 1996;120:189-198.
3. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfectin: The first 10 years. Clin Microbiol Rev 1997;10:298-319.
4. Badaro R, Benson D, Eulalio MC, et al. rK39: A cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 1996;173:758-761.
5. Berenguer J, Gomez-Campdera F, Padilla B, et al. Visceral leishmaniasis (kala-azar) in transplant recipients: Case report and review. Transplantation 1998;65:1401-1404.
6. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703.
7. Cascio A, Gradoni L, Scarlata F, et al. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy. Am J Trop Med Hyg 1997;57:75-78.
8. de Gorgolas M, Miles MA. Visceral leishmaniasis and AIDS. Nature 1994;372:734.
9. Gutierrez J. Prevalence of anti-Leishmania antibodies in parenteral drug addicts: Yield value of 2 study techniques. Med Clin 1993;100:168-174.
10. Houghton RL, Petrescu M, Benson DR, et al. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis 1998;177:1339-1344.
11. Laguna A, Adrados M, Alvar J, et al. Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1997;16:898-903.
12. Laguna F, Garcia-Samaniego J, Soriano V, et al. Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: report of five cases and review. Clin Infect Dis 1994;19:48-53.
13. Lopez-Velez R, Perez-Molina JA, Guerrero A, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 1998;58:436-443.
14. Magill AJ. Epidemiology of leishmaniases. Dermatol Clin 1995;13:505-523.
15. Martinez P, de la Vega E, Laguna F, et al. Diagnosis of visceral leishmaniasis in HTV-infected individuals using peripheral blood smears. AIDS 1993;7:227-230.
16. Murray HW, Hariprashad J, Fichtl RE. Treatment of experimental visceral leishmaniasis in a T cell-deficient host: Response to amphotericin B and pentamidine. Antimicrob. Agents Chemother 1993;37:1504-1507.
17. Murray HW. Granulomatous inflammation: Host antimicrobial defense in the tissues in visceral leishmanisis. In: Gallin JI, Snydeman R, Fearon DT, Haynes BF, Nathan CF, eds. Inflammation: Basic Principes and Clinical Correlates, 3rd ed. Philadelphia: Lippincott-Williams & Wilkins, 1999:977-994.
18. Murray HW, Oca MJ, Granger AM, Schreiber RD. Successful response to chemotherapy in experimental visceral leishmaniasis: Requirement for T cells and effect of lymphokines. J Clin Invest 1989;83:1253-1259.
19. Paredes R, Laguna F, Clotet B. Leishmaniasis in HTV-infected persons: A review. J Int Assoc Phys AIDS Care 1997;June:22-39.
20. Parkas V, Godwin J, Murray HW. Kala-azar comes to New York. Arch Intern Med 1997;157:921-922.
21. Pearson RD, de Queiroz Sousa A. Clinical spectrum of leishmaniasis. Clin Infect Dis 1996;22:1-13.
22. Peters BS, Fish D, Golden R, eta 1. Visceral leishmaniasis in HIV infection and AIDS: Clinical features and response to therapy. Q J Med 1990;77:1101-1111.
23. Presier W, Cacopardo B, Nigro I, et al. Immunological findings in HTV-Leishmania coinfection. Intervirology 1996;39:285-288.
24. Ribera E, Ocana I, de Otero J, et al. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996;100:496-501.
25. Rosenthal E, Marty P, Poizit-Martin I, et al. Visceral leishmaniasis and HTV-1 co-infection in southern France. Trans Roy Soc Trop Med Hyg 1995;89:158-162.
26. Sasaki MGM, Carvalho MM, Ferreira MLS, Machado MP. Cutaneous leishmaniasis in AIDS patients: Case report and literature review. Braz J Infect Dis 1997;1:142-144.
27. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997;127:133-135.
28. Sundar S, Reed SG, Singh W, Kumar PCK, Murray HW. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 1998;351:563-566.
29. Sundar S, Rosenkaimer F, Lesser ML, Murray HW. Immunochemotherapy for a systemic intracellular infection: Accelerated response using interferon-gamma in visceral leishmaniasis. J Infect Dis 1995;171:992-996.
30. Sundar S, Rosenkaimer F, Makharia MK, et al. Oral treatment for visceral leishmaniasis: Miltefosine in Indian kala-azar. Lancet 1998;352:1821-1823.
31. World Health Organization. Weekly Epidemiol Record 1997;21 February:29-54.